JAVELIN Bladder 101: Study Design and Patient Outcomes

Video

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
5 experts in this video
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Related Content
"These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions," according to Keiji Inoue, MD, PhD, a professor in the Department of Urology at Kochi Medical School.

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

Russ Conroy
April 22nd 2025
Article

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC

Russ Conroy
April 8th 2025
Article

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC

Roman Fabbricatore
March 25th 2025
Article

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

A World of Research, Care, and Science: Becoming A Radiation Oncologist

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Tim Cortese
March 12th 2025
Article

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.